# Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)

> **NCT02953743** · PHASE1 · COMPLETED · sponsor: **Eisai Co., Ltd.** · enrollment: 25 (actual)

## Conditions studied

- Unresectable Hepatocellular Carcinoma (HCC)

## Interventions

- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT02953743
- **Lead sponsor:** Eisai Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-01
- **Primary completion:** 2017-06-28
- **Final completion:** 2020-12-28
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2021-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02953743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02953743, "Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT02953743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*